Aliases & Classifications for Ureteral Obstruction

MalaCards integrated aliases for Ureteral Obstruction:

Name: Ureteral Obstruction 12 55 44 15

External Ids:

Disease Ontology 12 DOID:5199
ICD9CM 35 593.4
MeSH 44 D014517
UMLS 73 C0029866

Summaries for Ureteral Obstruction

MalaCards based summary : Ureteral Obstruction is related to renal fibrosis and hydronephrosis. An important gene associated with Ureteral Obstruction is TGFB1 (Transforming Growth Factor Beta 1), and among its related pathways/superpathways are TGF-Beta Pathway and PAK Pathway. The drugs Tamsulosin and Silodosin have been mentioned in the context of this disorder. Affiliated tissues include kidney, prostate and bone, and related phenotypes are Increased shRNA abundance (Z-score > 2) and Increased shRNA abundance (Z-score > 2)

Related Diseases for Ureteral Obstruction

Diseases related to Ureteral Obstruction via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 167)
# Related Disease Score Top Affiliating Genes
1 renal fibrosis 31.0 TGFB1 BMP7 BMP6 AGTR1
2 hydronephrosis 30.9 TGFB1 SLC12A1 AQP2
3 chronic kidney failure 30.3 TGFB1 PTGS2 EPO AGTR1
4 urinary tract obstruction 30.3 TGFB1 PTGS2 AQP2
5 kidney disease 30.2 TGFB1 EPO BMP7 AQP2 AGTR2 AGTR1
6 colitis 29.6 PTGS2 NOS2 IL10 CTNNB1
7 familial adenomatous polyposis 29.3 TP53 PTGS2 CTNNB1
8 retroperitoneal fibrosis 10.4
9 endometriosis 10.3
10 vesicoureteral reflux 1 10.3
11 anuria 10.2
12 juvenile myasthenia gravis 10.2 TGFB1 IL10
13 familial vesicoureteral reflux 10.2 TGFB1 AGTR2
14 inflammatory bowel disease 25, autosomal recessive 10.2 TGFB1 IL10
15 posterior urethral valves 10.2 TGFB1 AGTR2 AGTR1
16 fibrosclerosis, multifocal 10.2
17 cystitis 10.2
18 malakoplakia 10.2
19 obstructive nephropathy 10.1
20 aortic aneurysm 10.1
21 end stage renal failure 10.1 TGFB1 EPO AGTR1
22 chagas disease 10.1 TGFB1 NOS2 IL10
23 leptospirosis 10.1 SLC9A3 SLC12A1 IL10
24 leukoregulin 10.1 TGFB1 PTGS2
25 sarcoma 10.1
26 lipomatosis 10.1
27 pelvic lipomatosis 10.1
28 hypoxia 10.1
29 adult hepatocellular carcinoma 10.1 TP53 CTNNB1
30 proteasome-associated autoinflammatory syndrome 1 10.1 PTGS2 NOS2 IL10
31 aortic aneurysm, familial abdominal, 1 10.1
32 pyelonephritis 10.1
33 ischemia 10.1
34 pancreatitis 10.1
35 appendicitis 10.1
36 protoplasmic astrocytoma 10.0 TP53 PTGS2
37 esophagitis 10.0 TP53 TGFB1 PTGS2
38 gastrointestinal system benign neoplasm 10.0 TP53 PTGS2 CTNNB1
39 hypertension, essential 10.0 SLC12A1 NOS2 AGTR2 AGTR1
40 intestinal benign neoplasm 10.0 TP53 PTGS2 CTNNB1
41 prostate cancer 10.0
42 reticulum cell sarcoma 10.0
43 cervical cancer 10.0
44 inguinal hernia 10.0
45 thrombosis 10.0
46 schistosomiasis 10.0
47 glandular cystitis 10.0
48 purpura 10.0
49 actinomycosis 10.0
50 renal dysplasia 10.0

Graphical network of the top 20 diseases related to Ureteral Obstruction:



Diseases related to Ureteral Obstruction

Symptoms & Phenotypes for Ureteral Obstruction

GenomeRNAi Phenotypes related to Ureteral Obstruction according to GeneCards Suite gene sharing:

26 (show all 21)
# Description GenomeRNAi Source Accession Score Top Affiliating Genes
1 Increased shRNA abundance (Z-score > 2) GR00366-A-105 9.72 TGFB1
2 Increased shRNA abundance (Z-score > 2) GR00366-A-110 9.72 AGTR1
3 Increased shRNA abundance (Z-score > 2) GR00366-A-12 9.72 TP53
4 Increased shRNA abundance (Z-score > 2) GR00366-A-120 9.72 TGFB1 TP53
5 Increased shRNA abundance (Z-score > 2) GR00366-A-123 9.72 AGTR1
6 Increased shRNA abundance (Z-score > 2) GR00366-A-132 9.72 TP53
7 Increased shRNA abundance (Z-score > 2) GR00366-A-140 9.72 TGFB1
8 Increased shRNA abundance (Z-score > 2) GR00366-A-143 9.72 TGFB1
9 Increased shRNA abundance (Z-score > 2) GR00366-A-168 9.72 AGTR1
10 Increased shRNA abundance (Z-score > 2) GR00366-A-169 9.72 TGFB1 TP53
11 Increased shRNA abundance (Z-score > 2) GR00366-A-177 9.72 AGTR1
12 Increased shRNA abundance (Z-score > 2) GR00366-A-178 9.72 TGFB1
13 Increased shRNA abundance (Z-score > 2) GR00366-A-19 9.72 TP53
14 Increased shRNA abundance (Z-score > 2) GR00366-A-190 9.72 TP53
15 Increased shRNA abundance (Z-score > 2) GR00366-A-198 9.72 TGFB1
16 Increased shRNA abundance (Z-score > 2) GR00366-A-207 9.72 AGTR1
17 Increased shRNA abundance (Z-score > 2) GR00366-A-35 9.72 AGTR1 TGFB1 TP53
18 Increased shRNA abundance (Z-score > 2) GR00366-A-39 9.72 TP53
19 Increased shRNA abundance (Z-score > 2) GR00366-A-49 9.72 AGTR1
20 Increased shRNA abundance (Z-score > 2) GR00366-A-56 9.72 TGFB1
21 Increased shRNA abundance (Z-score > 2) GR00366-A-79 9.72 AGTR1

MGI Mouse Phenotypes related to Ureteral Obstruction:

46 (show all 24)
# Description MGI Source Accession Score Top Affiliating Genes
1 cardiovascular system MP:0005385 10.51 AGTR1 AGTR2 BMP7 CTNNB1 EPO IL10
2 homeostasis/metabolism MP:0005376 10.44 AGTR1 AGTR2 AQP2 CTNNB1 EPO IL10
3 growth/size/body region MP:0005378 10.4 AGTR1 AGTR2 AQP2 BMP6 BMP7 CTNNB1
4 behavior/neurological MP:0005386 10.39 AGTR1 AGTR2 AQP2 BMP7 CTNNB1 IL10
5 mortality/aging MP:0010768 10.38 AGTR1 AGTR2 AQP2 BMP7 CTNNB1 EPO
6 hematopoietic system MP:0005397 10.36 AGTR1 AQP2 BMP7 CTNNB1 EPO IL10
7 cellular MP:0005384 10.34 AGTR2 CTNNB1 EPO IL10 LRP2 NOS2
8 immune system MP:0005387 10.34 AGTR1 BMP7 CTNNB1 EPO IL10 LRP2
9 endocrine/exocrine gland MP:0005379 10.31 AGTR2 BMP7 CTNNB1 IL10 LRP2 NOS2
10 digestive/alimentary MP:0005381 10.28 AGTR2 BMP7 CTNNB1 IL10 LRP2 NOS2
11 integument MP:0010771 10.25 AGTR2 AQP2 BMP7 CTNNB1 EPO IL10
12 embryo MP:0005380 10.23 BMP7 CTNNB1 EPO IL10 LRP2 PTGS2
13 nervous system MP:0003631 10.18 AGTR1 AGTR2 BMP7 CTNNB1 IL10 LRP2
14 adipose tissue MP:0005375 10.16 AGTR1 AGTR2 NOS2 PTGS2 SLC9A3 TGFB1
15 muscle MP:0005369 10.16 AGTR2 CTNNB1 EPO IL10 NOS2 NOX4
16 craniofacial MP:0005382 10.14 BMP7 CTNNB1 IL10 LRP2 NOS2 TGFB1
17 renal/urinary system MP:0005367 10.13 AGTR1 AGTR2 AQP2 BMP7 CTNNB1 LRP2
18 liver/biliary system MP:0005370 10.04 CTNNB1 EPO IL10 NOS2 PTGS2 TGFB1
19 reproductive system MP:0005389 10.03 AQP2 BMP6 BMP7 CTNNB1 IL10 LRP2
20 neoplasm MP:0002006 9.98 AGTR2 CTNNB1 IL10 NOS2 PTGS2 TGFB1
21 no phenotypic analysis MP:0003012 9.91 CTNNB1 IL10 LRP2 NOX4 PTGS2 SPHK2
22 respiratory system MP:0005388 9.85 BMP7 CTNNB1 EPO IL10 LRP2 NOS2
23 skeleton MP:0005390 9.73 AGTR2 BMP6 BMP7 CTNNB1 EPO IL10
24 vision/eye MP:0005391 9.23 BMP7 CTNNB1 IL10 LRP2 NOS2 PTGS2

Drugs & Therapeutics for Ureteral Obstruction

Drugs for Ureteral Obstruction (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 74)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Tamsulosin Approved, Investigational Phase 4,Not Applicable 106133-20-4 129211
2
Silodosin Approved Phase 4 160970-54-7
3 Adrenergic alpha-1 Receptor Antagonists Phase 4,Not Applicable
4 Neurotransmitter Agents Phase 4,Phase 2,Not Applicable
5 Tolterodine tartrate Phase 4 124937-52-6
6 Adrenergic Antagonists Phase 4,Not Applicable
7 Muscarinic Antagonists Phase 4,Not Applicable
8 Cholinergic Antagonists Phase 4,Not Applicable
9 Adrenergic alpha-Antagonists Phase 4,Not Applicable
10 Cholinergic Agents Phase 4,Not Applicable
11 Adrenergic Agents Phase 4,Phase 2,Not Applicable
12 Coagulants Phase 3
13 Fibrin Tissue Adhesive Phase 3
14 Hemostatics Phase 3
15
Iodine Approved, Investigational Phase 2 7553-56-2 807
16
Triclosan Approved, Investigational Phase 2 3380-34-5 5564
17
Lidocaine Approved, Vet_approved Phase 2,Not Applicable 137-58-6 3676
18
Levoleucovorin Approved, Investigational Phase 2 68538-85-2
19
leucovorin Approved Phase 2 58-05-9 6006 143
20
Floxuridine Approved Phase 2 50-91-9 5790
21
Fluorouracil Approved Phase 2 51-21-8 3385
22 Mirabegron Approved Phase 2 223673-61-8
23
Gemcitabine Approved Phase 2 95058-81-4 60750
24
Folic Acid Approved, Nutraceutical, Vet_approved Phase 2 59-30-3 6037
25 Anesthetics Phase 2,Not Applicable
26 Antimetabolites Phase 2
27 Anti-Infective Agents, Local Phase 2
28 Lipid Regulating Agents Phase 2
29 Hypolipidemic Agents Phase 2
30 Anti-Infective Agents Phase 2,Not Applicable
31 Central Nervous System Depressants Phase 2,Not Applicable
32 Anesthetics, Local Phase 2,Not Applicable
33 Diuretics, Potassium Sparing Phase 2,Not Applicable
34 Sodium Channel Blockers Phase 2,Not Applicable
35 Anti-Arrhythmia Agents Phase 2,Not Applicable
36 Peripheral Nervous System Agents Phase 2,Not Applicable
37 Protective Agents Phase 2
38 Cola Phase 2
39 Calcium, Dietary Phase 2
40 Trace Elements Phase 2
41 Vitamin B Complex Phase 2
42 Vitamin B9 Phase 2
43 Vitamins Phase 2
44 Immunosuppressive Agents Phase 2
45 Micronutrients Phase 2
46 Folate Phase 2
47 Immunologic Factors Phase 2
48 Liver Extracts Phase 2
49 Antidotes Phase 2
50 Antimetabolites, Antineoplastic Phase 2

Interventional clinical trials:

(show all 36)
# Name Status NCT ID Phase Drugs
1 Efficacy and Safety of a Covered Self-expandable Dual-layered Metallic Mesh Stent (UVENTA) in Ureteral Obstruction Unknown status NCT01788865 Phase 4
2 Treatment of Symptoms After Stent Placement for Urinary Tract Obstruction Completed NCT01741454 Phase 4 Tamsulosin;Tolterodine ER
3 Functional MR Urography Completed NCT00301470 Phase 4
4 Efficacy and Safety of Silodosin in the Treatment of Natural Expulsion in Patients With Ureteral Stones Completed NCT01533389 Phase 4 Silodosin;Placebo
5 Fibrin Based Adhesive for the Prevention of Surgical Complications in the Kidney Transplantation Completed NCT01631448 Phase 3
6 Comparison of Silicone-covered Metallic Ureteral Stent and Double-J Stent for Malignant Ureteral Obstruction Unknown status NCT01823575 Phase 2
7 Tolerance and Effectiveness of Ureteral Stents MEMOKATH ® 051 in Chronic Strictures of the Ureter Completed NCT00790686 Phase 2
8 Assessment of Drug-eluting Ureteral Stent on Bacterial Adherence and Biofilm Formation Completed NCT00250406 Phase 2
9 Randomized Controlled Trial of Cystocele Plication Risks ("CPR Trial"): A Pilot Study Completed NCT01197248 Phase 2
10 A Randomized Control Trial Comparing Single vs. Multiple Application of Lidocaine Analgesia Prior to Urethral Catheterization Procedures Completed NCT00142064 Phase 2
11 Liver Resection and Floxuridine Plus Fluorouracil and Leucovorin in Treating Patients With Liver Metastases From Colorectal Cancer Completed NCT00002842 Phase 2 floxuridine;fluorouracil;leucovorin calcium
12 Mirabegron as Medical Expulsive Therapy (MET) for Ureteral Stones and Ureteral Stent Pain Recruiting NCT02744430 Phase 2 Mirabegron
13 Assessment of Gemcitabine as Chemoradiotherapy in Patients With Locally Advanced Carcinoma of Cervix and Renal Disease Recruiting NCT03101995 Phase 2 Gemcitabine
14 The Correlation Between Renal Injury and Biomarkers in Pediatric Ureteropelvic Junction Obstruction Patients Unknown status NCT01711996
15 Ureteropelvic Junction Obstruction in Early Childhood: Comparison of Surgical Therapy and Surveillance. A Prospective, Randomized, Controlled Multi-Center Study Unknown status NCT00444431 Not Applicable
16 Diagnostic Relevance of Laser Confocal Microscopy for the Screening of Upper Urinary Tract Tumors Unknown status NCT02276924 Not Applicable
17 Drainage of Malignant Extrinsic Ureteral Obstruction Using the Memokath Ureteral Stent Completed NCT00166361 Not Applicable
18 Urinary Biomarkers as Predictors on Renal Function in Congenital Hydronephrosis Completed NCT00568724
19 Laparoscopic Pyeloplasty Registry and Database Completed NCT00169650
20 Evaluating Ureteral Length Using Computed Tomography (CT) Completed NCT01542593 Not Applicable
21 The Efficacy and Safety of Local Anesthetic Infusion With Ropivacaine Completed NCT00930046 Not Applicable
22 Dismembered Pyeloplasty With and Without After Coming Stent Completed NCT02138877 Not Applicable
23 Perioperative Intravenous Lidocaine or Epidural Anesthesia on Outcomes in Complex Spine Surgery Completed NCT00840996 Not Applicable Lidocaine;placebo
24 Early Infancy Ureteral Reimplantation for Distal Ureteral Obstruction Recruiting NCT02419339
25 Trospium Chloride vs Tamsulosin in Treatment of Ureteral Stent Related Symptoms: Recruiting NCT03709992 Not Applicable Trospium Chloride;Tamsulosin
26 Cystoprostatectomy Versus Radiotherapy Combined With ADT for the Treatment of cT4 Prostate Cancer With Bladder Invasion Recruiting NCT03482089 Not Applicable
27 Multi-Center Comparison of Dual Lumen Versus Single Lumen Ureteroscopes Recruiting NCT02123082 Not Applicable
28 Local Treatment With RP for Newly-diagnosed mPCa Recruiting NCT02138721 Not Applicable
29 Randomized Trial of NSAID vs Placebo Prior to Ureteral Stent Removal Recruiting NCT02140970 Not Applicable Ibuprofen;Placebo
30 Nonabsorbable Versus Absorbable Sutures for Anterior Colporrhaphy Recruiting NCT03736811 Not Applicable
31 Ureteral Reimplantation for the Treatment of Extrinsic Malignant Ureteral Obstruction Enrolling by invitation NCT02160652
32 The RELIEF™ Ureteral Stent - Assessment of Retrograde Urinary Reflux and Distal Coil Bladder Position Not yet recruiting NCT03266770 Not Applicable
33 Ureteral Stent Versus Percutaneous Nephrostomy in Acutely Obstructed Infected Kidney Not yet recruiting NCT03498794 Not Applicable
34 CTT on Renogram as an Early Marker of Significant Obstruction in Uretero-pelvic Junction Syndrome Not yet recruiting NCT02812212 Not Applicable
35 Indwelling Double-J Ureteral Stent Versus Externalized Modified-Salle Stent for Pyeloplasty Terminated NCT02713633 Not Applicable
36 Comparison of Dynamic Contrast Enhanced CT and Diuretic Renogram in The Evaluation of UPJO Withdrawn NCT00199472

Search NIH Clinical Center for Ureteral Obstruction

Cochrane evidence based reviews: ureteral obstruction

Genetic Tests for Ureteral Obstruction

Anatomical Context for Ureteral Obstruction

MalaCards organs/tissues related to Ureteral Obstruction:

41
Kidney, Prostate, Bone, Endothelial, Cervix, Colon, Monocytes

Publications for Ureteral Obstruction

Articles related to Ureteral Obstruction:

(show top 50) (show all 1048)
# Title Authors Year
1
Ablation of C/EBP homologous protein attenuates renal fibrosis after ureteral obstruction by reducing autophagy and microtubule disruption. ( 29425932 )
2018
2
Effects of Qingshen Granules on the Oxidative Stress-NF/kB Signal Pathway in Unilateral Ureteral Obstruction Rats. ( 29576795 )
2018
3
pNaKtide ameliorates renal interstitial fibrosis through inhibition of sodium-potassium adenosine triphosphatase-mediated signaling pathways in unilateral ureteral obstruction mice. ( 29788096 )
2018
4
The effect of darbepoetin alfa on renal fibrosis in rats with acute unilateral ureteral obstruction. ( 29521269 )
2018
5
What are the predictive factors leading to ureteral obstruction following endoscopic correction of VUR in the pediatric population? ( 29885870 )
2018
6
Cryptotanshinone Attenuates Oxidative Stress and Inflammation through the Regulation of Nrf-2 and NF-I_B in Mice with Unilateral Ureteral Obstruction. ( 29972887 )
2018
7
Ureteral obstruction and ruptured kidney following ovarian hyperstimulation syndrome. ( 29391290 )
2018
8
Cell-intrinsic sphingosine kinase 2 promotes macrophage polarization and renal inflammation in response to unilateral ureteral obstruction. ( 29518138 )
2018
9
Ureteral Obstruction Secondary to an Appendiceal Mucocele: A Case Report and Literature Review. ( 29845117 )
2018
10
Evaluation of renal metabolic response to partial ureteral obstruction with hyperpolarized<sup>13</sup>C MRI. ( 29130537 )
2018
11
Is hydrogen sulfide a potential novel therapy to prevent renal damage during ureteral obstruction? ( 29269061 )
2018
12
Outcome of ureteral stent placement for treatment of benign ureteral obstruction in dogs: 44 cases (2010-2013). ( 29504861 )
2018
13
Vimentin expression is required for the development of EMT-related renal fibrosis following Unilateral Ureteral Obstruction in mice. ( 29631355 )
2018
14
Ultrasonography in the diagnosis and management of cats with ureteral obstruction. ( 29172872 )
2018
15
No difference in renal injury and fibrosis between wild-type and NOD1/NOD2 double knockout mice with chronic kidney disease induced by ureteral obstruction. ( 29609537 )
2018
16
As in Real Estate, Location Is What Matters: A Case Report of Transplant Ureteral Obstruction Due to an Inguinal Hernia. ( 29372065 )
2018
17
Adenovirus-mediated P311 ameliorates renal fibrosis through inhibition of epithelial-mesenchymal transition via TGF-I^1-Smad-ILK pathway in unilateral ureteral obstruction rats. ( 29436600 )
2018
18
Thioredoxin-interacting protein deficiency ameliorates kidney inflammation and fibrosis in mice with unilateral ureteral obstruction. ( 29884908 )
2018
19
Encrusted Cystitis with Suspected Ureteral Obstruction Following Cystoscopic-Guided Laser Ablation of Ectopic Ureters in a Dog. ( 29372865 )
2018
20
Renal parenchyma impairment characterization in partial unilateral ureteral obstruction in mice with intravoxel incoherent motion-MRI. ( 29178439 )
2018
21
Comparison of T1 Mapping and T1rho Values with Conventional Diffusion-weighted Imaging to Assess Fibrosis in a Rat Model of Unilateral Ureteral Obstruction. ( 29705280 )
2018
22
Specific Inhibitor of Smad3 (SIS3) Attenuates Fibrosis, Apoptosis, and Inflammation in Unilateral Ureteral Obstruction Kidneys by Inhibition of Transforming Growth Factor I^ (TGF-I^)/Smad3 Signaling. ( 29555895 )
2018
23
Bone marrowa89derived mesenchymal stem cella89conditioned medium attenuates tubulointerstitial fibrosis by inhibiting monocyte mobilization in an irreversible model of unilateral ureteral obstruction. ( 29620281 )
2018
24
Comparison of single and tandem ureteral stenting for malignant ureteral obstruction: a prospective study of 104 patients. ( 29974220 )
2018
25
First Experience of Inserting a Metallic Mesh Stent (Uventa Stent) in Malignant Ureteral Obstruction in Iran. ( 29427286 )
2018
26
A Prospective Randomized Comparison of a Covered Metallic Ureteral Stent and a Double-J Stent for Malignant Ureteral Obstruction. ( 29962867 )
2018
27
Validation of a model of feline ureteral obstruction as a tool for teaching microsurgery to veterinary surgeons. ( 29380880 )
2018
28
Laparoscopic management of severe ureteral obstruction after vaginal hysterectomy and colposuspension. ( 29855661 )
2018
29
Effects of cholecalciferol cholesterol emulsion on renal fibrosis and aquaporin 2 and 4 in mice with unilateral ureteral obstruction. ( 29602131 )
2018
30
PEGylated pUR4/FUD peptide inhibitor of fibronectin fibrillogenesis decreases fibrosis in murine Unilateral Ureteral Obstruction model of kidney disease. ( 30356276 )
2018
31
Ureteral obstruction by sloughed tumor complicating cryoablation of a renal oncocytoma. ( 30533167 )
2018
32
Subcutaneous ureteral bypass for treatment of bilateral ureteral obstruction in a cat with retroperitoneal paraganglioma. ( 30311526 )
2018
33
Apoptosis-Associated Speck-Like Protein Containing a CARD Deletion Ameliorates Unilateral Ureteral Obstruction Induced Renal Fibrosis and Endoplasmic Reticulum Stress in Mice. ( 30057487 )
2018
34
Evaluating Renal Fibrosis with R2* Histogram Analysis of the Whole Cortex in a Unilateral Ureteral Obstruction Model. ( 30111497 )
2018
35
Deubiquitinase inhibitor PR-619 reduces Smad4 expression and suppresses renal fibrosis in mice with unilateral ureteral obstruction. ( 30114247 )
2018
36
HL156A, a novel pharmacological agent with potent adenosine-monophosphate-activated protein kinase (AMPK) activator activity ameliorates renal fibrosis in a rat unilateral ureteral obstruction model. ( 30161162 )
2018
37
Fluorofenidone attenuates interleukin-1β production by interacting with NLRP3 inflammasome in unilateral ureteral obstruction. ( 28437591 )
2018
38
Ultrasound evaluation of the renal pelvis in cats with ureteral obstruction treated with a subcutaneous ureteral bypass: a retrospective study of 27 cases (2010-2015). ( 28980849 )
2018
39
Does a Ureteral Obstruction Affect the Contralateral Kidney Morphology? A Stereological Analysis in a Rodent Model. ( 29421794 )
2018
40
The Role of Mas Receptor on Renal Hemodynamic Responses to Angiotensin 1-7 in Both Irreversible and Reversible Unilateral Ureteral Obstruction Rats. ( 29456983 )
2018
41
Glomerular hyperpermeability after acute unilateral ureteral obstruction: effects of Tempol, NOS, RhoA, and Rac-1 inhibition. ( 29465305 )
2018
42
Application of resonance metallic stents for malignant ureteral obstruction. ( 29475395 )
2018
43
Identification of transcripts associated with renal damage due to ureteral obstruction as candidate urinary biomarkers. ( 29488389 )
2018
44
Use of a modified Boari flap for the treatment of a proximal ureteral obstruction in a cat. ( 29504132 )
2018
45
The renal protect function of erythropoietin after release of bilateral ureteral obstruction in a rat model. ( 29959186 )
2018
46
Metabolic Response in Rabbit Urine to Occurrence and Relief of Unilateral Ureteral Obstruction. ( 30024170 )
2018
47
Testosterone and Mast Cell Interactions in the Development of Kidney Fibrosis after Unilateral Ureteral Obstruction in Rats. ( 30068865 )
2018
48
Nigella sativa extract is a potent therapeutic agent for renal inflammation, apoptosis, and oxidative stress in a rat model of unilateral ureteral obstruction. ( 30070029 )
2018
49
Beneficial effects of Oltipraz, nuclear factor - erythroid - 2 - related factor 2 (Nrf2), on renal damage in unilateral ureteral obstruction rat model. ( 30130014 )
2018
50
Pentoxifylline protects against loss of function and renal interstitial fibrosis in chronic experimental partial ureteral obstruction. ( 30197294 )
2018

Variations for Ureteral Obstruction

Expression for Ureteral Obstruction

Search GEO for disease gene expression data for Ureteral Obstruction.

Pathways for Ureteral Obstruction

Pathways related to Ureteral Obstruction according to GeneCards Suite gene sharing:

(show all 34)
# Super pathways Score Top Affiliating Genes
1
Show member pathways
13.41 AGTR1 AGTR2 BMP6 BMP7 EPO IL10
2
Show member pathways
13.22 BMP6 BMP7 CTNNB1 IL10 NOX4 TGFB1
3
Show member pathways
12.95 BMP6 BMP7 CTNNB1 NOS2 PTGS2 VEGFC
4
Show member pathways
12.92 AGTR1 AGTR2 BMP6 BMP7 PTGS2 TGFB1
5
Show member pathways
12.48 AGTR1 CTNNB1 IL10 NOS2 TP53
6
Show member pathways
12.4 BMP7 CTNNB1 NOX4 TGFB1
7
Show member pathways
12.32 CTNNB1 NOS2 PTGS2 SPHK2
8
Show member pathways
12.32 BMP6 BMP7 CTNNB1 TGFB1 VEGFC
9
Show member pathways
12.17 IL10 NOS2 PTGS2 TGFB1
10 12.15 BMP6 BMP7 CTNNB1 TGFB1
11 12.13 IL10 NOS2 SPHK2 TGFB1
12
Show member pathways
12.09 BMP6 BMP7 IL10 TGFB1 TP53 VEGFC
13 12.05 BMP6 BMP7 CTNNB1 TGFB1
14
Show member pathways
11.98 BMP6 BMP7 IL10 TGFB1 VEGFC
15 11.98 CTNNB1 NOS2 PTGS2 TGFB1 TP53
16 11.95 AGTR1 CTNNB1 EPO NOS2 PTGS2 TGFB1
17 11.94 BMP6 BMP7 CTNNB1 TGFB1 TP53
18 11.82 IL10 NOS2 TGFB1
19 11.81 AGTR1 NOX4 TGFB1 VEGFC
20 11.8 NOS2 PTGS2 TP53
21 11.77 PTGS2 TGFB1 VEGFC
22 11.74 BMP6 BMP7 TGFB1
23 11.73 NOS2 NOX4 PTGS2 TGFB1 TP53
24
Show member pathways
11.71 AGTR1 AGTR2 TGFB1
25 11.65 BMP6 BMP7 TGFB1 VEGFC
26 11.63 IL10 NOS2 PTGS2 TGFB1
27 11.61 BMP6 BMP7 TGFB1
28 11.61 IL10 NOS2 PTGS2 TGFB1 TP53
29 11.56 BMP6 BMP7 CTNNB1 TGFB1 TP53
30 11.49 EPO TP53 VEGFC
31 11.33 NOS2 PTGS2 TGFB1 TP53
32 11.26 NOS2 PTGS2 TP53
33 10.95 BMP6 BMP7 IL10 TGFB1 VEGFC
34 10.82 EPO NOS2 PTGS2 TP53

GO Terms for Ureteral Obstruction

Cellular components related to Ureteral Obstruction according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 apical plasma membrane GO:0016324 9.02 AQP2 LRP2 NOX4 SLC12A1 SLC9A3

Biological processes related to Ureteral Obstruction according to GeneCards Suite gene sharing:

(show all 46)
# Name GO ID Score Top Affiliating Genes
1 response to drug GO:0042493 9.99 CTNNB1 IL10 PTGS2 TGFB1 VEGFC
2 regulation of signaling receptor activity GO:0010469 9.99 BMP6 BMP7 EPO IL10 TGFB1 VEGFC
3 positive regulation of transcription, DNA-templated GO:0045893 9.98 AGTR2 BMP7 CTNNB1 EPO IL10 TGFB1
4 cytokine-mediated signaling pathway GO:0019221 9.97 IL10 NOS2 PTGS2 TGFB1 TP53
5 cell proliferation GO:0008283 9.95 CTNNB1 EPO LRP2 SPHK2 TGFB1 TP53
6 response to lipopolysaccharide GO:0032496 9.93 EPO IL10 NOS2 PTGS2
7 inflammatory response GO:0006954 9.93 AGTR2 BMP6 IL10 NOX4 PTGS2 TGFB1
8 response to organic substance GO:0010033 9.87 IL10 PTGS2 TGFB1
9 positive regulation of neuron differentiation GO:0045666 9.87 BMP6 BMP7 EPO
10 cellular response to mechanical stimulus GO:0071260 9.86 BMP6 PTGS2 TGFB1
11 positive regulation of endothelial cell proliferation GO:0001938 9.85 BMP6 IL10 VEGFC
12 kidney development GO:0001822 9.85 AGTR1 BMP6 BMP7 CTNNB1
13 response to glucocorticoid GO:0051384 9.84 BMP6 IL10 PTGS2
14 positive regulation of epithelial cell proliferation GO:0050679 9.83 BMP6 TGFB1 VEGFC
15 cell development GO:0048468 9.83 BMP6 BMP7 TGFB1
16 positive regulation of osteoblast differentiation GO:0045669 9.83 BMP6 BMP7 CTNNB1
17 response to estradiol GO:0032355 9.83 BMP7 CTNNB1 PTGS2 TGFB1
18 regulation of MAPK cascade GO:0043408 9.82 BMP6 BMP7 TGFB1
19 SMAD protein signal transduction GO:0060395 9.82 BMP6 BMP7 TGFB1
20 positive regulation of pathway-restricted SMAD protein phosphorylation GO:0010862 9.8 BMP6 BMP7 TGFB1
21 negative regulation of cell cycle GO:0045786 9.8 BMP7 PTGS2 TGFB1
22 aging GO:0007568 9.8 EPO IL10 NOX4 PTGS2 TGFB1
23 positive regulation of epithelial to mesenchymal transition GO:0010718 9.79 BMP7 CTNNB1 TGFB1
24 positive regulation of protein secretion GO:0050714 9.78 BMP6 TGFB1 VEGFC
25 epithelial to mesenchymal transition GO:0001837 9.77 BMP7 CTNNB1 TGFB1
26 regulation of cell proliferation GO:0042127 9.77 AGTR1 CTNNB1 NOS2 PTGS2 TGFB1
27 positive regulation of bone mineralization GO:0030501 9.75 BMP6 BMP7 TGFB1
28 positive regulation of reactive oxygen species metabolic process GO:2000379 9.73 AGTR1 NOX4 TP53
29 positive regulation of apoptotic process GO:0043065 9.73 BMP7 CTNNB1 NOX4 PTGS2 TGFB1 TP53
30 response to hypoxia GO:0001666 9.72 EPO NOS2 NOX4 TGFB1 VEGFC
31 positive regulation of pri-miRNA transcription by RNA polymerase II GO:1902895 9.71 IL10 TGFB1 TP53
32 positive regulation of heterotypic cell-cell adhesion GO:0034116 9.7 BMP7 IL10
33 regulation of blood vessel diameter GO:0097746 9.7 AGTR1 AGTR2
34 morphogenesis of embryonic epithelium GO:0016331 9.69 CTNNB1 VEGFC
35 positive regulation of SMAD protein signal transduction GO:0060391 9.68 BMP6 TGFB1
36 salivary gland morphogenesis GO:0007435 9.68 BMP7 TGFB1
37 angiotensin-activated signaling pathway GO:0038166 9.67 AGTR1 AGTR2
38 positive regulation of production of miRNAs involved in gene silencing by miRNA GO:1903800 9.67 TGFB1 TP53
39 response to vitamin D GO:0033280 9.67 BMP7 PTGS2 TGFB1
40 regulation of protein import into nucleus GO:0042306 9.66 AGTR2 TGFB1
41 negative regulation of intrinsic apoptotic signaling pathway in response to osmotic stress GO:1902219 9.64 EPO PTGS2
42 regulation of apoptotic process GO:0042981 9.63 AGTR2 BMP6 BMP7 CTNNB1 TGFB1 TP53
43 renin-angiotensin regulation of aldosterone production GO:0002018 9.61 AGTR1 AGTR2
44 negative regulation of cell proliferation GO:0008285 9.5 BMP7 CTNNB1 IL10 NOX4 PTGS2 TGFB1
45 positive regulation of cell proliferation GO:0008284 9.23 AGTR2 BMP6 CTNNB1 EPO PTGS2 SPHK2
46 negative regulation of apoptotic process GO:0043066 10.06 CTNNB1 EPO IL10 PTGS2 SPHK2 TP53

Molecular functions related to Ureteral Obstruction according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 protein heterodimerization activity GO:0046982 9.8 AGTR1 BMP6 CTNNB1 TGFB1 TP53
2 transforming growth factor beta receptor binding GO:0005160 9.43 BMP6 BMP7 TGFB1
3 BMP receptor binding GO:0070700 9.37 BMP6 BMP7
4 cytokine activity GO:0005125 9.35 BMP6 BMP7 EPO IL10 TGFB1
5 angiotensin type II receptor activity GO:0004945 9.32 AGTR1 AGTR2
6 growth factor activity GO:0008083 9.02 BMP6 BMP7 IL10 TGFB1 VEGFC
7 protein binding GO:0005515 10.09 AGTR1 AGTR2 AQP2 BMP7 CTNNB1 EPO

Sources for Ureteral Obstruction

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
17 ExPASy
19 FMA
28 GO
29 GTR
30 HGMD
31 HMDB
32 HPO
33 ICD10
34 ICD10 via Orphanet
35 ICD9CM
36 IUPHAR
37 KEGG
38 LifeMap
40 LOVD
42 MedGen
44 MeSH
45 MESH via Orphanet
46 MGI
49 NCI
50 NCIt
51 NDF-RT
54 NINDS
55 Novoseek
57 OMIM
58 OMIM via Orphanet
62 PubMed
64 QIAGEN
69 SNOMED-CT via HPO
70 SNOMED-CT via Orphanet
71 TGDB
72 Tocris
73 UMLS
74 UMLS via Orphanet
Content
Loading form....